A Real-world study assessing efficacy and safety of venetoclax combinations in T(11;14) multiple myeloma
Latest Information Update: 07 Aug 2021
Price :
$35 *
At a glance
- Drugs Dexamethasone (Primary) ; Venetoclax (Primary) ; Proteasome inhibitors
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 07 Aug 2021 New trial record
- 17 Jun 2021 Results presented at the 26th Congress of the European Haematology Association